Clinical Trial Update: Ex Vivo-Expanded HER2-Specific T Cells and Cyclophosphamide After Vaccine Therapy in Treating Patients With HER2-Positive Stage IV Breast Cancer [Phase 1]

View source ↗

Summary

This clinical trial update notes the withdrawal of a Phase 1 study of ex vivo-expanded HER2-specific T cells with cyclophosphamide following vaccine therapy for…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Male Breast Cancer

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• ex vivo-expanded HER2-specific T cells (HER2-specific T cells)

Snippet

Sponsor: University of Washington | Conditions: HER2-positive Breast Cancer, Male Breast Cancer | Phase 1 | Status: WITHDRAWN